Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999–2018 and an exploratory hospital-based dataset - Report - MDSpire
Advertisement
Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999–2018 and an exploratory hospital-based dataset
Clinical Report: Association of Elevated Framingham Steatosis Index with Breast Cancer
Overview
This study investigates the association between the Framingham Steatosis Index (FSI) and prevalent breast cancer in women using NHANES data from 1999 to 2018. Higher FSI was linked to increased odds of breast cancer.
Background
Breast cancer is the most commonly diagnosed cancer among women globally, presenting a significant public health challenge. Recent research has highlighted the role of metabolic dysfunction and hepatic steatosis in the epidemiology of breast cancer.
Data Highlights
Measure
Value
Participants
21,042
Breast cancer prevalence
2.5% (531 women)
Odds Ratio (1-unit increase in FSI)
1.10 (95% CI 1.05–1.16)
Odds Ratio (after age adjustment)
1.02 (95% CI 0.96–1.07)
Key Findings
Among 21,042 women, 2.5% reported a history of breast cancer.
Each 1-unit increase in FSI was associated with higher odds of prevalent breast cancer (OR 1.10).
After adjusting for age, the association between FSI and breast cancer was no longer statistically significant (OR 1.02).
Higher FSI quartiles correlated with greater odds of prevalent breast cancer.
Restricted cubic spline analysis indicated a non-linear association between FSI and breast cancer.
In an exploratory hospital dataset, FSI was positively associated with breast cancer case status when modeled continuously.
Clinical Implications
The findings indicate that FSI is associated with breast cancer, but its interpretation should consider age as a significant factor.
Conclusion
The study highlights the association between metabolic indices and breast cancer.
